Focus: AbbVie is a $54.3B revenue Big Pharma company with a diverse portfolio spanning immunology, oncology, neuroscience, aesthetics, and eye care, operating at significant scale with 50,000 employees. The company maintains a balanced small-molecule and biologics capability across both innovative drugs and established revenue generators.
Profile data last refreshed 22h ago · AI intelligence enriched 4w ago
Recent layoff filing — 85 affected
Source: state DOL filings via Big Local News
No open roles listed right now. Follow AbbVie to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from AbbVie's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Protein kinase inhibitor representing 19% of company revenue with 9-year patent protection remaining.
Help build intelligence for AbbVie
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Guanylate cyclase activator generating $1.8B annually with LOE protection through early 2034.
Calcineurin inhibitor for dry eye with sustained revenue and patent protection until May 2034.
Biologic digestive enzyme replacement therapy approaching loss of exclusivity.
JAK inhibitor with strong patent protection through 2038 and multiple late-stage development programs.
Antipsychotic generating $936M but facing significant patent cliff in March 2030.
P-glycoprotein inhibitor oncology asset with 8+ years of patent protection and extensive clinical trial activity (48 trials).
Thyroid hormone replacement therapy nearing patent expiration with limited growth prospects.
298 discontinued, 57 duplicate formulations not shown
+31 more products with revenue data
+2 more
8-K Filing: TCGX Acquisition Corp. (TCGX) (CIK 0002137965) — EX-99.2
EX-99.2
Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today. - Barron's
Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today. Barron's
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? Zacks Investment Research
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Yahoo Finance
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? Yahoo Finance
8-K Filing: Harmony Biosciences Holdings, Inc. (HRMY) (CIK 0001802665) — EX-99.1
EX-99.1
Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks - 24/7 Wall St.
Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks 24/7 Wall St.
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent peer-reviewed publications with author affiliations at this company
+30 more products
+1 more
+2 more
+2 more
+2 more
+2 more
+2 more
Documented layoffs in 2025–2026 and recent revenue contraction represent immediate risk; restructuring appears ongoing rather than concluded.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo